Abstract
A methotrexate (MTX)-loaded layered double hydroxide (LDH) nanoparticle system was synthesized by intercalating MTX into the interlayer spaces of LDH. In vivo pharmacokinetic study demonstrated that the MTX-LDH hybrid had similar kinetic behaviors as free MTX, showing a rapid decline in the plasma MTX level, with characteristics of a biexponential function. However, the hybrid system remarkably suppressed tumor growth in human osteosarcoma-bearing mice compared to an equivalent amount of free MTX. Using MTX-LDH nanoparticles, a significantly high amount of MTX was delivered to target tumor tissue, whereas a low level was found in normal tissues. Moreover, LDH nanocarriers did not accumulate in any specific tissue nor cause acute toxicity up to the applied dose for the hybrid system. These results suggest that the MTX-LDH nanohybrid system has great potential as an anti-cancer drug with enhanced in vivo anti-tumor activity and bioavailability in target tumor tissue along with reduced side effects.
Keywords: layered double hydroxide, methotrexate, anti-tumor activity, pharmacokinetics, toxicity.
Current Pharmaceutical Design
Title:In Vivo Anticancer Activity of Methotrexate-loaded Layered Double Hydroxide Nanoparticles
Volume: 19 Issue: 41
Author(s): Soo-Jin Choi, Jae-Min Oh, Hae-Eun Chung, Seung-Hee Hong, In-Hoo Kim and Jin-Ho Choy
Affiliation:
Keywords: layered double hydroxide, methotrexate, anti-tumor activity, pharmacokinetics, toxicity.
Abstract: A methotrexate (MTX)-loaded layered double hydroxide (LDH) nanoparticle system was synthesized by intercalating MTX into the interlayer spaces of LDH. In vivo pharmacokinetic study demonstrated that the MTX-LDH hybrid had similar kinetic behaviors as free MTX, showing a rapid decline in the plasma MTX level, with characteristics of a biexponential function. However, the hybrid system remarkably suppressed tumor growth in human osteosarcoma-bearing mice compared to an equivalent amount of free MTX. Using MTX-LDH nanoparticles, a significantly high amount of MTX was delivered to target tumor tissue, whereas a low level was found in normal tissues. Moreover, LDH nanocarriers did not accumulate in any specific tissue nor cause acute toxicity up to the applied dose for the hybrid system. These results suggest that the MTX-LDH nanohybrid system has great potential as an anti-cancer drug with enhanced in vivo anti-tumor activity and bioavailability in target tumor tissue along with reduced side effects.
Export Options
About this article
Cite this article as:
Choi Soo-Jin, Oh Jae-Min, Chung Hae-Eun, Hong Seung-Hee, Kim In-Hoo and Choy Jin-Ho, In Vivo Anticancer Activity of Methotrexate-loaded Layered Double Hydroxide Nanoparticles, Current Pharmaceutical Design 2013; 19 (41) . https://dx.doi.org/10.2174/138161281941131219123718
DOI https://dx.doi.org/10.2174/138161281941131219123718 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer
Current Cancer Drug Targets CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Gene Delivery by Functional Inorganic Nanocarriers
Recent Patents on DNA & Gene Sequences Hecogenin Acetate Inhibits Reactive Oxygen Species Production and Induces Cell Cycle Arrest and Senescence in the A549 Human Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets BMP-9 Induced Osteogenic Differentiation of Mesenchymal Stem Cells: Molecular Mechanism and Therapeutic Potential
Current Gene Therapy Oral and Intravenous Ibandronate in the Management of Postmenopausal Osteoporosis: A Comprehensive Review
Current Pharmaceutical Design Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting
Current Drug Targets Application of Radiolabeled Antibodies in Targeting Therapy of Breast Cancer
Current Molecular Imaging (Discontinued) Cellular Systems Biology Profiling Applied to Cellular Models of Disease
Combinatorial Chemistry & High Throughput Screening Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation Gene Therapy in In Vivo Isolated Perfusion Models
Current Gene Therapy Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors
Recent Patents on Anti-Cancer Drug Discovery Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Recent Design and Structure-Activity Relationship Studies on the Modifications of DHFR Inhibitors as Anticancer Agents
Current Medicinal Chemistry Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry